Kala Bio (KALA) Share-based Compensation (2016 - 2026)
Kala Bio (KALA) posted Share-based Compensation of -$471000.0 for Q1 2026, up 90.66% sequentially from -$5.0 million in Q4 2025, and down 120.39% YoY from $2.3 million in Q1 2025.
Kala Bio (KALA) Share-based Compensation (2016 - 2026) Analysis & Trends
Kala Bio has reported Share-based Compensation for 11 years, with the latest figure at -$471000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 120.39% year-over-year to -$471000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 million (down 119.31% YoY) and the FY2025 annual result came in at $1.6 million, down 73.35% from the prior year.
- Share-based Compensation rose to -$471000.0 in Q1 2026 per KALA's latest filing, from -$5.0 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $5.3 million in Q4 2023 and troughed at -$5.0 million in Q4 2025.
- A 5-year average of $1.5 million and a median of $1.9 million in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation surged 450.31% in 2023, then plunged 3948.09% in 2025.
- Over 5 years, Share-based Compensation stood at $960000.0 in 2022, then soared by 450.31% to $5.3 million in 2023, then sank by 97.52% to $131000.0 in 2024, then slumped by 3948.09% to -$5.0 million in 2025, then jumped by 90.66% to -$471000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered -$471000.0, -$5.0 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kala Bio | 10.01 Mn | 10.01 Mn | - | 1.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -471,000.00 |
| Mar 31, 2026 | -471,000.00 |
| Dec 31, 2025 | -5.04 Mn |
| Dec 31, 2025 | -5.04 Mn |
| Sep 30, 2025 | 2.04 Mn |
| Sep 30, 2025 | 2.04 Mn |
| Jun 30, 2025 | 2.24 Mn |
| Jun 30, 2025 | 2.24 Mn |
| Mar 31, 2025 | 2.31 Mn |
| Mar 31, 2025 | 2.31 Mn |
| Dec 31, 2024 | 131,000.00 |
| Dec 31, 2024 | 131,000.00 |
| Sep 30, 2024 | 2.04 Mn |
| Sep 30, 2024 | 2.04 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Mar 31, 2024 | 2.38 Mn |
| Mar 31, 2024 | 2.38 Mn |
| Dec 31, 2023 | 5.28 Mn |
| Dec 31, 2023 | 5.28 Mn |